Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
- PMID: 16962883
- DOI: 10.1016/S0140-6736(06)69374-4
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
Abstract
Background: Hepatitis B and hepatitis C virus infections are common causes of death related to liver disease. In this large study, we aimed to investigate all cause mortality of the viruses in a community-based setting.
Methods: In the study population, 39,109 people had hepatitis B, 75,834 had hepatitis C, and 2604 had hepatitis B and hepatitis C co-infection, notified to the New South Wales state health department, Australia, between 1990 and 2002. Their data were probabilistically linked to the National Death Index. Standardised mortality ratios for all causes of death were calculated and adjusted for age, sex, and calendar year.
Results: The number of deaths identified by the linkage were 1233 (3.2%) for hepatitis B, 4008 (5.3)% for hepatitis C, and 186 (7.1)% for hepatitis B and C co-infection. Raised risk of liver-related death (standardised mortality ratios 12.2, 95% CI 10.7-13.9; 16.8, 15.4-18.3, and 32.9, 23.1-46.7, for hepatitis B, hepatitis C, and hepatitis B and C co-infected patients, respectively) and drug-induced death (1.4, 1.0-2.0; 19.3, 18.1-20.5; and 24.7, 18.2-33.5, respectively) were detected. In people with hepatitis C, raised risk of dying from drug-related causes was significantly greater than from liver-related causes (p=0.012), with the greatest excess risk in women aged 15-24 years (56.9, 39.2-79.9).
Interpretation: All groups had increased risk of liver-related death compared with the standard population, with the greatest excess in people diagnosed with hepatitis B and hepatitis C co-infection. Our data highlight that young people with hepatitis C and with co-infection face a higher mortality risk from continued drug use than from their infection, whereas the main cause of hepatitis B death was liver related.
Comment in
-
Prevention of mortality from hepatitis B and hepatitis C.Lancet. 2006 Sep 9;368(9539):896-7. doi: 10.1016/S0140-6736(06)69347-1. Lancet. 2006. PMID: 16962862 No abstract available.
-
Mortality in patients with hepatitis B or hepatitis C.Lancet. 2006 Nov 18;368(9549):1767; author reply 1767. doi: 10.1016/S0140-6736(06)69728-6. Lancet. 2006. PMID: 17113419 No abstract available.
-
Causes of death in hepatitis B and/or C virus infected-people - lessons for clinical practice.Hepatology. 2007 Apr;45(4):1076-7. doi: 10.1002/hep.21621. Hepatology. 2007. PMID: 17393502 No abstract available.
-
Causes of death in hepatitis B and C: a methodological issue.Lancet. 2007 Sep 22;370(9592):1033. doi: 10.1016/S0140-6736(07)61473-1. Lancet. 2007. PMID: 17889239 No abstract available.
Similar articles
-
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study.J Hepatol. 2006 Aug;45(2):197-203. doi: 10.1016/j.jhep.2006.02.014. Epub 2006 Mar 31. J Hepatol. 2006. PMID: 16684579
-
Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study.Aust N Z J Public Health. 2007 Oct;31(5):475-82. doi: 10.1111/j.1753-6405.2007.00121.x. Aust N Z J Public Health. 2007. PMID: 17931297
-
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.J Hepatol. 2011 May;54(5):879-86. doi: 10.1016/j.jhep.2010.08.035. Epub 2010 Oct 23. J Hepatol. 2011. PMID: 21145812
-
Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity.Oncogene. 2006 Jun 26;25(27):3771-7. doi: 10.1038/sj.onc.1209560. Oncogene. 2006. PMID: 16799618 Review.
-
Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.Anticancer Res. 2006 Sep-Oct;26(5A):3293-300. Anticancer Res. 2006. PMID: 17094443 Review.
Cited by
-
Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.PLoS One. 2019 Dec 19;14(12):e0226566. doi: 10.1371/journal.pone.0226566. eCollection 2019. PLoS One. 2019. PMID: 31856222 Free PMC article.
-
Excess mortality among people with communicable diseases over a 30-year period, Victoria, Australia: a whole of population cohort study.Lancet Reg Health West Pac. 2023 Jun 20;38:100815. doi: 10.1016/j.lanwpc.2023.100815. eCollection 2023 Sep. Lancet Reg Health West Pac. 2023. PMID: 37790083 Free PMC article.
-
HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection.Sci Rep. 2016 Dec 23;6:39409. doi: 10.1038/srep39409. Sci Rep. 2016. PMID: 28009018 Free PMC article.
-
Chronic hepatitis B: what should be the goal for new therapies?Antiviral Res. 2013 Apr;98(1):27-34. doi: 10.1016/j.antiviral.2013.01.006. Epub 2013 Feb 4. Antiviral Res. 2013. PMID: 23391846 Free PMC article.
-
Model of life expectancy of chronic hepatitis B carriers in an endemic region.J Epidemiol. 2009;19(6):311-8. doi: 10.2188/jea.je20090039. Epub 2009 Oct 3. J Epidemiol. 2009. PMID: 19801886 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical